+65 3158 9940
1300 798 820
+64 9801 0299
Singapore, 22 September 2021: SINGAPORE patients with an aggressive form of lung cancer (metastatic small cell cung cancer) can now access a new therapy that may improve outcomes. The drug ZEPZELCA (lurbinectedin) has been provisionally approved by Singapore’s Health Sciences Authority (HSA) “for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. Timing Question 00:00:00 For recurrent desmoids or
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. Timing Question 00:01:15 After STRASS 1, the
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”c37cJBTkekA&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”Dg-Fv0UALMw&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”sr4nyJ0WVB0&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
The following presentations may contain off-label content and data concerning products not currently registered in Australia. Specialised Therapeutics does not recommend or endorse off-label use or use of products that are not registered in Australia. These videos are intended for healthcare professionals for informative purposes only. [video_lightbox_youtube video_id=”ZHlheozCiuQ&rel=0″ width=”1522″ height=”775″ anchor=”Click Here To Watch The
Singapore, 14 September 2021: AUSTRALIAN patients with an aggressive form of lung cancer (metastatic Small Cell Lung Cancer) can now access a new therapy that may improve outcomes. The therapy, ZEPZELCA™ (lurbinectedin) has been approved by the Therapeutic Goods Administration (TGA) “for the treatment of patients with metastatic small cell lung cancer (SCLC) that has progressed
Singapore and Melbourne, Australia, 4 April, 2017: Independent pharmaceutical company Specialised Therapeutics Asia (ST Asia) will today relaunch a product used to relieve the pain of oral mucositis, a condition that can affect cancer patients undergoing chemotherapy and/or radiotherapy. GELCLAIR is a bio-adherent oral gel that works by creating a protective film in the mouth,
Melbourne, Australia, 1 February 2017: International biopharmaceutical company Specialised Therapeutics will today launch a new company business model, as part of a bold plan to improve relationships with healthcare professionals. Under this plan, sales teams will no longer be paid bonuses based on the number of prescriptions written. Instead, in field representatives will be rewarded